Christopher Benecchi

Chief Commercial Officer, Sage Therapeutics, Inc.

Companies

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Jul 31, 2025Returned to company 36,375 shares of Sage Therapeutics, Inc.³
Jul 31, 2025Returned to company 28,053 shares of Sage Therapeutics, Inc.³
Apr 10, 2025Shares withheld for tax 661 shares at $6.91 of Sage Therapeutics, Inc.⁴
Apr 10, 2025Granted 2,712 shares of Sage Therapeutics, Inc.⁴
Apr 10, 2025Shares withheld for tax 793 shares at $6.91 of Sage Therapeutics, Inc.⁴
Apr 10, 2025Granted 3,255 shares of Sage Therapeutics, Inc.⁴
Feb 13, 2025Shares withheld for tax 822 shares at $7.18 of Sage Therapeutics, Inc.⁵
Jan 16, 2025Granted 20,000 shares of Sage Therapeutics, Inc.⁶
Nov 1, 2024Granted 6,250 shares of Sage Therapeutics, Inc.⁷
Aug 5, 2024Shares withheld for tax 4,755 shares at $8.96 of Sage Therapeutics, Inc.⁸
Aug 5, 2024Granted 16,200 shares of Sage Therapeutics, Inc.⁸
Feb 13, 2024Granted 13,500 shares of Sage Therapeutics, Inc.⁹
Feb 3, 2023Shares withheld for tax 2,119 shares at $44.16 of Sage Therapeutics, Inc.¹⁰
Feb 3, 2023Granted 6,750 shares of Sage Therapeutics, Inc.¹⁰

The numbers on this page point here. Each one links to the record it came from.